Currently out of the existing stock ratings of Katherine Breedis, 5 are a BUY (100%).

Katherine Breedis

Work Performance Price Targets & Ratings Chart

Analyst Katherine Breedis, carries an average stock price target met ratio of 50% that have a potential upside of 40.48% achieved within 1465 days. Previously, Katherine Breedis worked at STIFEL.

Katherine Breedis’s has documented 10 price targets and ratings displayed on 2 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on VYGR, Voyager Therapeutics at 28-Jul-2017.

Wall Street Analyst Katherine Breedis

Analyst best performing recommendations are on GILD (GILEAD SCIENCES).

Average potential price target upside

GILD Gilead Sciences VYGR Voyager Therapeutics

Analyst name

Rating

Rating initiation date

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Hold

Since 07-Jan-2026

$145

$23.9 (19.74%)

$85

3 days ago
(07-Jan-2026)

32/33 (96.97%)

$23.64 (19.48%)

1412

Buy

Since 14-Nov-2024

$140

$18.9 (15.61%)

$135

3 days ago
(07-Jan-2026)

16/18 (88.89%)

$18.64 (15.36%)

1167

Buy

Since 10-Jan-2025

$151

$29.9 (24.69%)

$135

29 days ago
(12-Dec-2025)

30/33 (90.91%)

$27.79 (22.55%)

603

Buy

Since 07-Oct-2024

$150

$28.9 (23.86%)

$140

1 months ago
(10-Dec-2025)

17/19 (89.47%)

$28.66 (23.62%)

478

Buy

Since 03-Nov-2025

$140

$18.9 (15.61%)

$145

1 months 17 days ago
(24-Nov-2025)

2/4 (50%)

$13.36 (10.55%)

73

Show more analysts

Please expand the browser size to see the chart

What Year was the first public recommendation made by Katherine Breedis?

On 2016

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?